Last 12 months
Inside the activity.
0 purchase rows · 31 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 5 |
| Dec 2025 | 0 | 4 |
| Jan 2026 | 0 | 4 |
| Feb 2026 | 0 | 4 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 3 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 2 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 1 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 11, 2019 Filed Nov 14, 2019 00:47 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock | 6,651 | $43.63 | $290,183.13 |
DisclosureSEC source: 0001127602-19-032669 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,067 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · balance_after: Includes 183.40 shares of ResMed stock purchased on October 31, 2019, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| November 11, 2019 Filed Nov 14, 2019 00:12 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
Tax withholdingResMed Common Stock | 6,365 | $143.88 | $915,796.20 |
DisclosureSEC source: 0001127602-19-032662 · form4.xml · nonDerivative · entry 2 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,476 F3 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2016. Read SEC document |
| November 11, 2019 Filed Nov 14, 2019 00:12 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
Tax withholdingResMed Common Stock | 2,416 | $143.88 | $347,614.08 |
DisclosureSEC source: 0001127602-19-032662 · form4.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,841 F1 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2017. F2 · balance_after: Includes 117.14 shares of ResMed stock purchased on October 31, 2019, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| November 04, 2019 Filed Nov 6, 2019 00:47 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 4,367 | $0.00 Strike: $52.02 | $0.00 |
DisclosureSEC source: 0001127602-19-031968 · form4.xml · derivative · entry 4 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Commmon Stock · 4,367 shares Expires 2021-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| November 04, 2019 Filed Nov 6, 2019 00:47 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
GiftResMed Common Stock | 6,823 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-031968 · form4.xml · nonDerivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,591 F2 · kind: Gift of shares to The San Diego Foundation Mr. Pendarvis has no beneficial interest, control or dispositive power over the gifted shares. Read SEC document |
| November 04, 2019 Filed Nov 6, 2019 00:47 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 4,367 | $147.85 | $645,660.95 |
DisclosureSEC source: 0001127602-19-031968 · form4.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,414 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| November 04, 2019 Filed Nov 6, 2019 00:47 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock | 4,367 | $52.02 | $227,171.34 |
DisclosureSEC source: 0001127602-19-031968 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,781 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| November 04, 2019 Filed Nov 5, 2019 19:57 UTC |
WAREHAM JOHN PDirector
|
Exercise / conversionResMed Common Stock Options · Derivative | 5,956 | $0.00 Strike: $58.24 | $0.00 |
DisclosureSEC source: 0001127602-19-031852 · form4.xml · derivative · entry 10 WAREHAM JOHN P · CIK 0001231182 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Commmon Stock · 5,956 shares Expires 2022-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 04, 2019 Filed Nov 5, 2019 19:57 UTC |
WAREHAM JOHN PDirector
|
Exercise / conversionResMed Common Stock Options · Derivative | 5,000 | $0.00 Strike: $58.24 | $0.00 |
DisclosureSEC source: 0001127602-19-031852 · form4.xml · derivative · entry 9 WAREHAM JOHN P · CIK 0001231182 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,956 Underlying: ResMed Commmon Stock · 5,000 shares Expires 2022-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 04, 2019 Filed Nov 5, 2019 19:57 UTC |
WAREHAM JOHN PDirector
|
GiftResMed Common Stock | 1,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-031852 · form4.xml · nonDerivative · entry 7 WAREHAM JOHN P · CIK 0001231182 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,300 F2 · kind: Gift of shares to Washington University in St. Louis. Mr. Wareham has no beneficial interest, control or dispositive power over the gifted shares. Read SEC document |
| November 04, 2019 Filed Nov 5, 2019 19:57 UTC |
WAREHAM JOHN PDirector
|
SaleResMed Common Stock | 5,956 | $148.00 | $881,488.00 |
DisclosureSEC source: 0001127602-19-031852 · form4.xml · nonDerivative · entry 6 WAREHAM JOHN P · CIK 0001231182 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,400 Read SEC document |
| November 04, 2019 Filed Nov 5, 2019 19:57 UTC |
WAREHAM JOHN PDirector
|
Exercise / conversionResMed Common Stock | 5,956 | $58.24 | $346,877.44 |
DisclosureSEC source: 0001127602-19-031852 · form4.xml · nonDerivative · entry 5 WAREHAM JOHN P · CIK 0001231182 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,356 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 04, 2019 Filed Nov 5, 2019 19:57 UTC |
WAREHAM JOHN PDirector
|
SaleResMed Common Stock | 5,000 | $147.75 | $738,750.00 |
DisclosureSEC source: 0001127602-19-031852 · form4.xml · nonDerivative · entry 4 WAREHAM JOHN P · CIK 0001231182 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,400 Read SEC document |
| November 04, 2019 Filed Nov 5, 2019 19:57 UTC |
WAREHAM JOHN PDirector
|
Exercise / conversionResMed Common Stock | 5,000 | $58.24 | $291,200.00 |
DisclosureSEC source: 0001127602-19-031852 · form4.xml · nonDerivative · entry 3 WAREHAM JOHN P · CIK 0001231182 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 20:23 UTC |
Hollingshead JamesPresident, Sleep Business
|
Exercise / conversionResMed Common Stock Options · Derivative | 800 | $0.00 Strike: $58.24 | $0.00 |
DisclosureSEC source: 0001127602-19-031861 · form4.xml · derivative · entry 4 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,555 Underlying: ResMed Commmon Stock · 800 shares Expires 2022-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 20:23 UTC |
Hollingshead JamesPresident, Sleep Business
|
SaleResMed Common Stock | 800 | $148.92 | $119,136.00 |
DisclosureSEC source: 0001127602-19-031861 · form4.xml · nonDerivative · entry 3 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,046 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 20:23 UTC |
Hollingshead JamesPresident, Sleep Business
|
SaleResMed Common Stock | 800 | $148.92 | $119,136.00 |
DisclosureSEC source: 0001127602-19-031861 · form4.xml · nonDerivative · entry 2 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,846 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 20:23 UTC |
Hollingshead JamesPresident, Sleep Business
|
Exercise / conversionResMed Common Stock | 800 | $58.24 | $46,592.00 |
DisclosureSEC source: 0001127602-19-031861 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,646 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 20:19 UTC |
Sodhi RajwantPresident, SaaS Business
|
SaleResMed Common Stock | 1,350 | $148.92 | $201,042.00 |
DisclosureSEC source: 0001127602-19-031859 · form4.xml · nonDerivative · entry 1 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,552 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 19:57 UTC |
WAREHAM JOHN PDirector
|
Exercise / conversionResMed Common Stock Options · Derivative | 9,536 | $0.00 Strike: $58.24 | $0.00 |
DisclosureSEC source: 0001127602-19-031852 · form4.xml · derivative · entry 8 WAREHAM JOHN P · CIK 0001231182 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,956 Underlying: ResMed Commmon Stock · 9,536 shares Expires 2022-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 19:57 UTC |
WAREHAM JOHN PDirector
|
SaleResMed Common Stock | 9,536 | $148.15 | $1,412,729.79 |
DisclosureSEC source: 0001127602-19-031852 · form4.xml · nonDerivative · entry 2 WAREHAM JOHN P · CIK 0001231182 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,400 F1 · price: This transaction was executed in multiple trades at prices ranging from $148.00 to $148.52. The price reported above reflects the weighted average sale price. Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 19:57 UTC |
WAREHAM JOHN PDirector
|
Exercise / conversionResMed Common Stock | 9,536 | $58.24 | $555,376.64 |
DisclosureSEC source: 0001127602-19-031852 · form4.xml · nonDerivative · entry 1 WAREHAM JOHN P · CIK 0001231182 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,936 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 30, 2019 Filed Nov 1, 2019 18:01 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 3,000 | $145.95 | $437,850.00 |
DisclosureSEC source: 0001127602-19-031439 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,690 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| October 28, 2019 Filed Oct 30, 2019 18:46 UTC |
Burt CarolDirector
|
GiftResMed Common Stock | 695 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-031247 · form4.xml · nonDerivative · entry 1 Burt Carol · CIK 0001493926 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,478 F1 · kind: Represents a gift of shares to The Nature Concervancy, a charitable organization. Ms. Burt has no beneficial interest, control or dispositive power over the gifted shares. Read SEC document |
| October 24, 2019 Filed Oct 25, 2019 20:22 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
GrantResMed Common Stock | 5,726 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-031081 · form4.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,140 F1 · shares: Represents performance-based restricted stock units granted on November 14, 2018. The shares were earned on October 24, 2019, when the compensation committee certified that the performance metrics were met for this portion of the grant. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| October 24, 2019 Filed Oct 25, 2019 20:20 UTC |
McHale RichardPresident, RC Business
|
GrantResMed Common Stock | 1,781 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-031079 · form4.xml · nonDerivative · entry 1 McHale Richard · CIK 0001715326 · President, RC Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,191 F1 · kind: Represents performance-based restricted stock units granted on November 14, 2018. The shares were earned on October 24, 2019, when the compensation committee certified that the performance metrics were met for this portion of the grant. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. F1 · shares: Represents performance-based restricted stock units granted on November 14, 2018. The shares were earned on October 24, 2019, when the compensation committee certified that the performance metrics were met for this portion of the grant. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| October 24, 2019 Filed Oct 25, 2019 20:16 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
GrantResMed Common Stock | 2,163 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-031075 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,414 F1 · shares: Represents performance-based restricted stock units granted on November 14, 2018. The shares were earned on October 24, 2019, when the compensation committee certified that the performance metrics were met for this portion of the grant. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| October 24, 2019 Filed Oct 25, 2019 20:18 UTC |
Farrell Michael J.Chief Executive Officer
|
GrantResMed Common Stock | 8,908 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-031078 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,232 F1 · shares: Represents performance-based restricted stock units granted on November 14, 2018. The shares were earned on October 24, 2019, when the compensation committee certified that the performance metrics were met for this portion of the grant. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| October 24, 2019 Filed Oct 25, 2019 20:10 UTC |
Sodhi RajwantPresident, SaaS Business
|
GrantResMed Common Stock | 2,545 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-031072 · form4.xml · nonDerivative · entry 1 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,902 F1 · shares: Represents performance-based restricted stock units granted on November 14, 2018. The shares were earned on October 24, 2019, when the compensation committee certified that the performance metrics were met for this portion of the grant. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| October 24, 2019 Filed Oct 25, 2019 20:07 UTC |
Hollingshead JamesPresident, Sleep Business
|
GrantResMed Common Stock | 2,545 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-031068 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,846 F1 · shares: Represents performance-based restricted stock units granted on November 14, 2018. The shares were earned on October 24, 2019, when the compensation committee certified that the performance metrics were met for this portion of the grant. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| October 24, 2019 Filed Oct 25, 2019 20:04 UTC |
Sandercock BrettChief Financial Officer
|
GrantResMed Common Stock | 2,545 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-031064 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,690 F1 · shares: Represents performance-based restricted stock units granted on November 14, 2018. The shares were earned on October 24, 2019, when the compensation committee certified that the performance metrics were met for this portion of the grant. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| October 15, 2019 Filed Oct 16, 2019 21:57 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
Exercise / conversionResMed Common Stock Options · Derivative | 3,302 | $0.00 Strike: $43.63 | $0.00 |
DisclosureSEC source: 0001127602-19-030656 · form4.xml · derivative · entry 4 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Commmon Stock · 3,302 shares Expires 2020-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| October 15, 2019 Filed Oct 16, 2019 21:57 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
SaleResMed Common Stock | 774 | $130.25 | $100,813.50 |
DisclosureSEC source: 0001127602-19-030656 · form4.xml · nonDerivative · entry 3 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Indirect · Douglas Family Trust Disclosed balance after: 147,519 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| October 15, 2019 Filed Oct 16, 2019 21:57 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
SaleResMed Common Stock | 3,302 | $130.25 | $430,085.50 |
DisclosureSEC source: 0001127602-19-030656 · form4.xml · nonDerivative · entry 2 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,414 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| October 15, 2019 Filed Oct 16, 2019 21:57 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
Exercise / conversionResMed Common Stock | 3,302 | $43.63 | $144,066.26 |
DisclosureSEC source: 0001127602-19-030656 · form4.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,716 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| October 14, 2019 Filed Oct 15, 2019 18:33 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 6,651 | $0.00 Strike: $43.63 | $0.00 |
DisclosureSEC source: 0001127602-19-030499 · form4.xml · derivative · entry 4 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,600 Underlying: ResMed Commmon Stock · 6,651 shares Expires 2020-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| October 14, 2019 Filed Oct 15, 2019 18:33 UTC |
Farrell Michael J.Chief Executive Officer
|
SaleResMed Common Stock | 6,651 | $129.83 | $863,492.68 |
DisclosureSEC source: 0001127602-19-030499 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,324 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $129.57 to $130.16. The price reported above reflects the weighted average sale price. Read SEC document |
| October 14, 2019 Filed Oct 15, 2019 18:33 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock | 6,651 | $43.63 | $290,183.13 |
DisclosureSEC source: 0001127602-19-030499 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| October 03, 2019 Filed Oct 4, 2019 20:16 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 4,367 | $0.00 Strike: $52.02 | $0.00 |
DisclosureSEC source: 0001127602-19-030141 · form4.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,367 Underlying: ResMed Commmon Stock · 4,367 shares Expires 2021-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| October 03, 2019 Filed Oct 4, 2019 20:16 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 4,367 | $128.62 | $561,683.54 |
DisclosureSEC source: 0001127602-19-030141 · form4.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,251 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| October 03, 2019 Filed Oct 4, 2019 20:16 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock | 4,367 | $52.02 | $227,171.34 |
DisclosureSEC source: 0001127602-19-030141 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,618 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| October 01, 2019 Filed Oct 2, 2019 21:31 UTC |
Sodhi RajwantPresident, SaaS Business
|
SaleResMed Common Stock | 1,350 | $135.13 | $182,425.50 |
DisclosureSEC source: 0001127602-19-029775 · form4.xml · nonDerivative · entry 1 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,357 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| October 01, 2019 Filed Oct 2, 2019 17:46 UTC |
Hollingshead JamesPresident, Sleep Business
|
Exercise / conversionResMed Common Stock Options · Derivative | 800 | $0.00 Strike: $58.24 | $0.00 |
DisclosureSEC source: 0001127602-19-029606 · form4.xml · derivative · entry 4 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,355 Underlying: ResMed Commmon Stock · 800 shares Expires 2022-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| October 01, 2019 Filed Oct 2, 2019 17:46 UTC |
Hollingshead JamesPresident, Sleep Business
|
SaleResMed Common Stock | 800 | $135.13 | $108,104.00 |
DisclosureSEC source: 0001127602-19-029606 · form4.xml · nonDerivative · entry 3 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,301 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| October 01, 2019 Filed Oct 2, 2019 17:46 UTC |
Hollingshead JamesPresident, Sleep Business
|
SaleResMed Common Stock | 800 | $135.13 | $108,104.00 |
DisclosureSEC source: 0001127602-19-029606 · form4.xml · nonDerivative · entry 2 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,101 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| October 01, 2019 Filed Oct 2, 2019 17:46 UTC |
Hollingshead JamesPresident, Sleep Business
|
Exercise / conversionResMed Common Stock | 800 | $58.24 | $46,592.00 |
DisclosureSEC source: 0001127602-19-029606 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,901 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| September 30, 2019 Filed Oct 2, 2019 16:22 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 3,000 | $134.14 | $402,420.00 |
DisclosureSEC source: 0001127602-19-029591 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,145 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| September 16, 2019 Filed Sep 17, 2019 18:52 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
Exercise / conversionResMed Common Stock Options · Derivative | 3,307 | $0.00 Strike: $43.63 | $0.00 |
DisclosureSEC source: 0001127602-19-028561 · form4.xml · derivative · entry 4 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,302 Underlying: ResMed Commmon Stock · 3,307 shares Expires 2020-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| September 16, 2019 Filed Sep 17, 2019 18:52 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
SaleResMed Common Stock | 757 | $131.63 | $99,643.91 |
DisclosureSEC source: 0001127602-19-028561 · form4.xml · nonDerivative · entry 3 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Indirect · Douglas Family Trust Disclosed balance after: 148,293 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| September 16, 2019 Filed Sep 17, 2019 18:52 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
SaleResMed Common Stock | 3,307 | $131.63 | $435,300.41 |
DisclosureSEC source: 0001127602-19-028561 · form4.xml · nonDerivative · entry 2 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,414 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.